SZSE:300015 (China)
Â
Class A
Â¥
12.32
-0.010 (-0.08%)
Jul 2
Business Description
Aier Eye Hospital Group Co Ltd
NAICS : 622310
SIC : 8069
ISIN : CNE100000GR6
Share Class Description:
SZSE:300015: Class ACompare
Compare
Traded in other countries / regions
300015.China Index Membership
SZSE Component IndexCHINEXT Price IndexCSI 300 IndexiShares MSCI ACWI Ex US Index FundCSI 300 Index IPO Date
2009-10-30Description
Aier Eye Hospital Group Co Ltd provides international ophthalmic technology and management services in China. The company offers services in myopia surgery, cataract, pediatric, eye plastic surgery, myopia prevention and control to patients. The group also enables high-standard medical care.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.05 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.31 | |||||
| Debt-to-EBITDA | 1.35 | |||||
| Interest Coverage | 18.52 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 7.74 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.1 | |||||
| 3-Year EBITDA Growth Rate | 14 | |||||
| 3-Year EPS without NRI Growth Rate | -5.7 | |||||
| 3-Year FCF Growth Rate | 4.9 | |||||
| 3-Year Book Growth Rate | 21.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 20.15 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 12.63 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.64 | |||||
| 9-Day RSI | 49.48 | |||||
| 14-Day RSI | 47.21 | |||||
| 3-1 Month Momentum % | -6.41 | |||||
| 6-1 Month Momentum % | -2.44 | |||||
| 12-1 Month Momentum % | 20.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.62 | |||||
| Quick Ratio | 1.48 | |||||
| Cash Ratio | 1.07 | |||||
| Days Inventory | 30.59 | |||||
| Days Sales Outstanding | 34.04 | |||||
| Days Payable | 67.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.3 | |||||
| Dividend Payout Ratio | 0.38 | |||||
| 3-Year Dividend Growth Rate | 30.8 | |||||
| Forward Dividend Yield % | 1.3 | |||||
| 5-Year Yield-on-Cost % | 3.7 | |||||
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | 0.15 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.05 | |||||
| Operating Margin % | 22.81 | |||||
| Net Margin % | 16.99 | |||||
| EBITDA Margin % | 23.22 | |||||
| FCF Margin % | 16.35 | |||||
| ROE % | 18.15 | |||||
| ROA % | 11.34 | |||||
| ROIC % | 16.48 | |||||
| 3-Year ROIIC % | 6.54 | |||||
| ROC (Joel Greenblatt) % | 51.11 | |||||
| ROCE % | 19.37 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 30.8 | |||||
| Forward PE Ratio | 28.06 | |||||
| PE Ratio without NRI | 31.11 | |||||
| Shiller PE Ratio | 51.33 | |||||
| Price-to-Owner-Earnings | 45.64 | |||||
| PEG Ratio | 1.96 | |||||
| PS Ratio | 5.22 | |||||
| PB Ratio | 5.26 | |||||
| Price-to-Tangible-Book | 9.33 | |||||
| Price-to-Free-Cash-Flow | 31.93 | |||||
| Price-to-Operating-Cash-Flow | 21.1 | |||||
| EV-to-EBIT | 22.88 | |||||
| EV-to-EBITDA | 22.88 | |||||
| EV-to-Revenue | 5.31 | |||||
| EV-to-FCF | 32.68 | |||||
| Price-to-GF-Value | 0.61 | |||||
| Price-to-Projected-FCF | 2 | |||||
| Price-to-DCF (Earnings Based) | 1 | |||||
| Price-to-DCF (FCF Based) | 1.02 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.24 | |||||
| Price-to-Graham-Number | 3.59 | |||||
| Earnings Yield (Greenblatt) % | 4.37 | |||||
| FCF Yield % | 3.1 | |||||
| Forward Rate of Return (Yacktman) % | 16.85 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers